- BioNano Genomics Announced the Purchase of IrysTM System by BGI
- QIAGEN partners with BGI Tech to provide services based on the Human Gene Mutation Database (HGMD) in Greater China
- BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics’Advanced Platform
- BGI announces first flagship project with the Edinburgh Genome Foundry to synthesize the largest synthetic eukaryotic chromosome in the UK
- BGI Reports a Novel Gene for Salt Tolerance Found in Wild Soybean
- Researchers Develop a New Genome Editing Method, Bringing the Possibility of Patient-specific Gene Therapies Closer to Reality
- BGI Presents a High-quality Gene Catalog of Human Gut Microbiome, A Key to Understanding Human Health and Diseases
- BGI Reports the Evolutionary Adaptations of Tibetans May Benefited from Extinct Denisovans
- BGI Health Forms Partnership with University of Mayor in South America
- BGI Health and Sir Ganga Ram Hospital Collaborated to Introduce NIFTY Test to India
- BGI Health Joins Hand with Star Metropolis Clinical Laboratories to Provide Genetic Testing Service
- BGI-Hong Kong 3730 Production Center Begins Operating, Providing Fast and High-quality Sequencing Services
- China's genomics success shows big data challenges
- Joe Biden is wrong. China does innovate
- Mainland scientific research company BGI expands its Hong Kong operations
- BGI Plans to Sequence the World
Tel: +86-755-25031760Email: firstname.lastname@example.org
The Latest Study Published Online in Nature Sheds New Light on Future Research and Disease Assessment for Diabetes
September 26, 2012, Shenzhen, China – BGI announces the online publication in the international journal Nature of a novel metagenomic study on human gut microbiota and their potential impact on type 2 diabetes (T2D), the most common form of diabetes. This work lays an important foundation for comprehensively understanding the genetic characteristics of gut microbiota and their relationship to T2D risk, as well as providing a new way of classifying microbes detected by DNA sequence. The work here also opens the way for transferring the potential value of a gut-microbiota-based approach into a means for clinical assessment and diagnosis of patients at risk of this disease.
T2D is a major chronic disease of modern societies and threatens the health of populations throughout the world. The continual and rapid increase in the prevalence of T2D has created a race against time for researchers worldwide to find new approaches to diagnose and treat the disease. T2D is a heterogeneous and multifactorial disease, influenced by a number of different genetic and environmental factors. While there are treatments to modulate its impact available, there remains great need to improve these therapies, and the disease cannot be cured.
Considering the important impact of gut microbiota on human diseases, such as T2D, BGI in collaboration with other institutes has focused on mining the gut microbiota information with the aim of fully understanding their molecular characteristics and using this to benefit human health. In this study, using deep next-generation shotgun sequencing, they developed a protocol for carrying out a metagenome-wide association study (MGWAS), and used it in a two-stage MGWAS analysis to better defining T2D-associated metagenomic markers. They sequenced the gut microbial DNA from 345 Chinese patients with T2D and identified approximately 60,000 T2D-associated markers that might be useful for detecting and characterizing T2D.
Of note, in addition to this new method and identification of T2D associated, researchers developed the concept of metagenomic linkage group (MLG) that allows easy classification and description of the abundant metagenomic data in a taxonomic form that can be used to replace traditional taxonomic classification approaches. MLG can provide metagenomic species-level information even for unknown species, including bacterial species-specific regions on a chromosome, and mobile genetic elements, such as plasmids and bacteriophages.
In general, the researchers found that healthy individuals typically had a higher number of butyrate-producing bacteria, which the researchers theorize may play a protective role against several types of diseases. In the T2D patients, that saw an increase in the number of, opportunistic pathogens, with the type of pathogen being quite diverse from patient to patient. Such changes in the gut bacteria composition have recently been reported for colorectal cancer patients and ageing population.
Junjie Qin, Primary Investigator on this project at BGI, said, “Gut microbiota has been widely considered as an important contributor to many kinds of chronic disease, like type 2 diabetes. However, it is still unclear on what and how exactly these commensal microbes contribute to human health. BGI, with a great power for conducting such a large-scale and in-depth studies, will continue to develop more sophisticated tools, collect a larger amount of scientific evidence, and better exploit the industrial/clinical potential in this field than has been done before.”
Jun Wang, Executive Director of BGI, said, “As the human’s ‘second genome’, the gut microbiome has a tight relationship with human health. High-throughput sequencing technologies and Metagenomics serve as robust tools for researchers to comprehensively explore the gut microbiota related with diseases, and shed new light into disease prevention and treatment. I believe the epoch of personalized medicine based on gut microbiome is not far away.”
Public Communication Officer